Women in early-phase clinical drug trials: Have things changed over the past 20 years?

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 5, 2005, Pages 445-452

  Fleisch, Jeanette ^b   Fleisch, Markus C ^b   Thürmann, Petra A ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHLORZOXAZONE; CISAPRIDE; CLOZAPINE; CYCLOSPORIN; CYCLOSPORIN A; DESIPRAMINE; DIAZEPAM; DIETHYLSTILBESTROL; DIGOXIN; ERYTHROMYCIN; ETOPOSIDE; EVEROLIMUS; HALOFANTRINE; HALOPERIDOL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEFLOQUINE; MEVINOLIN; MIDAZOLAM; NEUROLEPTIC AGENT; NIFEDIPINE; PARACETAMOL; RAPAMYCIN; SAQUINAVIR; SOTALOL; THALIDOMIDE; UNINDEXED DRUG; VERAPAMIL;

ADENOCARCINOMA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG SPECIFICITY; FEMININITY; GENDER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MEDICAL LITERATURE; NOTE; PHOCOMELIA; PRIORITY JOURNAL; QT PROLONGATION; SEX RATIO; TORSADE DES POINTES; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VOLUNTEER;

ADULT; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; SEX CHARACTERISTICS; UNITED STATES; WOMEN;

EID: 28144446779     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.08.016     Document Type: Note

References (57)

1. P.F. Smith, Ku Yi-Min Sex differences in pharmacokinetics and pharmacodynamics Pharmacotherapy self-assessment program 4th ed. 2002 American College of Clinical Pharmacy Kansas City (MO) Book 11: Women's health
2. B. Meibohm, I. Beierle, H. Derendorf How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41 2002 329 342
3. P.A. Thuermann, B.C. Hompesch Influence of gender on the pharmacokinetics and pharmacodynamics of drugs Int J Clin Pharmacol Ther 36 1998 586 590
4. R. Wolbold, K. Klein, O. Burk, A.K. Nussler, P. Neuhaus, M. Eichelbaum Sex is a major determinant of CYP3A4 expression in human liver Hepatology 38 2003 978 988
5. M.M. Cotreau, L.L. von Moltke, D.J. Greenblatt The influence of age and sex on the clearance of cytochrome P450 3A substrates Clin Pharmacokinet 44 2005 33 60
6. E.L. Kinney, J. Trautmann, J.A. Gold, E.S. Vessel, R. Zelis Underrepresentation of women in new drug trials ramifications and remedies Ann Intern Med 95 1981 495 499
7. D.L. Schmucker, E.S. Vesell Underrepresentation of women in clinical drug trials Clin Pharmacol Ther 54 1993 11 15
8. R.M. Vidaver, B. Lafleur, C. Tong, R. Bradshaw, S.A. Marts Women subjects in NIH-funded clinical research literature lack of progress in both representation and analysis by sex J Womens Health Gend Based Med 9 2000 495 504
9. Food and Drug Administration General considerations for the clinical evaluation of drugs 1977 Government Printing Office (US) Washington (DC) Dept. of Health, Education, and Welfare (US) Publication No.: (FDA) 77-3040
10. Food and Drug Administration Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs 1993 Available from: URL: www.fda.gov/cder/guidance/old063fn.pdf. Accessed Oct 11, 2005
11. R.B. Merkatz, S.W. Junod Historical background of changes in FDA policy on the study and evaluation of drugs in women Acad Med 69 1994 703 707
12. The AIDS Clinical Trials Group D.J. Cotton, D.M. Finkelstein, W. He, J. Feinberg Determinants of accrual of women to a large, multicenter clinical trial program of human immunodeficiency virus infection J Acquir Immune Defic Syndr 6 1993 1322 1328
13. T. Van den Bosch, D. Mattison, B. Ward Women in clinical trials screening and consent issues revisited Res Pract 1 2000 17 20
14. U. Halbreich, S.W. Carson Drug studies in women of childbearing age ethical and methodological issues J Clin Psychopharmacol 9 1989 328 333
15. T. Tateishi, M. Watanabe, H. Nakura, M. Asoh, H. Shirai, Y. Mizorogi CYP3A activity in European, American and Japanese men using midazolam as an in vivo probe Clin Pharmacol Ther 69 2001 333 339
16. S.N. De Wildt, G.L. Kearns, W.C. Hop, D.J. Murry, S.M. Abdel-Rahman, J.N. van den Anker Pharmacokinetics and metabolism of intravenous midazolam in preterm infants Clin Pharmacol Ther 70 2001 525 531
17. J.L. Palmer, R.J. Scott, A. Gibson, M. Dickins, S. Pleasance An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2EI) and midazolam (CYP3A) Br J Clin Pharmacol 52 2001 555 561
18. K. Lindhardt, S. Gizurarson, S.B. Stefansson, D.R. Olafsson, E. Bechgaard Electro-encephalographic effect and serum concentrations after nasal and intravenous administration of diazepam to healthy volunteers Br J Clin Pharmacol 52 2001 521 527
19. 2- microglobulin a potential use for digoxin intoxication Clin Pharmacol Ther 69 2001 422 430
20. L. Bequemont, C. Verstuyft, R. Kerb, U. Brinkmann, M. Lebot, P. Jaillon Effect of grapefruit juice on digoxin pharmacokinetics in humans Clin Pharmacol Ther 70 2001 311 316
21. F. Suematso, E. Yukawa, M. Yukawa, M. Minemoto, S. Ohdo, S. Higuchi Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-through screen analysis Eur J Clin Pharmacol 57 2001 19 24
22. T. Miura, R. Kojima, M. Mizutani, Y. Shiga, F. Takatsu, Y. Suzuki Effect of digoxin noncompliance on hospitalization and mortality in patients with heart failure in long-term therapy a prospective cohort study Eur J Clin Pharmacol 57 2001 77 83
23. C. Van der Marel, R. Van Lingen, M.A. Pluim, G. Scoones, M. van Dijk, J.M. Vaandrager Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery Clin Pharmacol Ther 70 2001 82 90
24. L. James, H. Farrar, T.L. Darville, J.E. Sullivan, T.G. Givens, G.L. Kearns Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents Clin Pharmacol Ther 70 2001 280 286
25. B.J. Anderson, G.A. Woollard, N.H.G. Holford Acetaminophen analgesia in children placebo effect and pain resolution after tonsillectomy Eur J Clin Pharmacol 57 2001 559 569
26. C. Kyrklund, J. Backman, K.T. Kivisto, M. Neuvonen, J. Laitila, P. Neuvonen Plasma concentration of lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin Pharmacol Ther 69 2001 340 345
27. A. Mulder, H. Van Lijf, M.A. Bon, F.A. van den Bergh, D.J. Touw, C. Neef Association of polymorphism in the cytochrome CYP2D6 and the efficacy and the tolerability of simvastatin Clin Pharmacol Ther 70 2001 546 551
28. K. Suginoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin Clin Pharmacol Ther 70 2001 518 524
29. C. Simard, G.E. O'Hara, J. Prevost, R. Guilbaud, R. Massee, J. Turgeon Study of the drug-drug interaction between simvastatin and cisapride in man Eur J Clin Pharmacol 57 2001 229 234
30. O. Von Richter, B. Greiner, M.F. Fromm, R. Fraser, T. Omari, M.L. Barclay Determination of in vivo absorption, metabolism and transport of drugs by the human intestinal wall and liver with a novel perfusion technique Clin Pharmacol Ther 70 2001 217 227
31. D. Busse, M. Fromm, K. Morike, S. Drescher, V. Kuhlkamp, M. Eichelbaum Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation an investigation comparing single and multiple dosing Clin Pharmacol Ther 69 2001 324 332
32. J. Lefrandt, J. Heitmann, K. Sevre, M. Castellano, M. Hausberg, M. Fallon Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension Br J Clin Pharmacol 52 2001 687 692
33. K. Raaska, V. Raitasuo, P.J. Neuvonen Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia Eur J Clin Pharmacol 57 2001 705 708
34. J.L. Pretorius, M. Phillips, R.W. Langley, E. Szabadi, C.M. Bradshaw Comparison of clozapine and haloperidol on some autonomic and psychomotor functions and on serum prolactin concentration in healthy subjects Br J Clin Pharmacol 52 2001 322 326
35. S. Tsunoda, R. Harris, U. Christians, R.L. Velez, R.B. Freeman, L.Z. Benet Red vine decreases cyclosporine bioavailability Clin Pharmacol Ther 70 2001 462 467
36. C.M. Stein, A.J. Sadeque, J.J. Murray, C. Wandel, R.B. Kim, A.J. Wood Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects Clin Pharmacol Ther 69 2001 317 323
37. G. Toffoli, G. Corona, R. Sorio, I. Robieux, B. Basso, A.M. Colussi Population pharmacokinetics and pharmacodynamics of oral etoposide Br J Clin Pharmacol 52 2001 511 519
38. C.M.E. Tranfa, A. Vatrella, R. Parrella, G. Peleia, F. Bariffi, S.A. Marsico Effect of inhaled heparin on water-induced bronchoconstriction in allergic asthmatics Eur J Clin Pharmacol 57 2001 5 9
39. K. Melkersson, A.L. Hulting, A. Rane Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses Br J Clin Pharmacol 51 2001 317 324
40. T.K. Bergmann, L. Bathum, K. Brosen Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6 Eur J Clin Pharmacol 57 2001 123 127
41. S. Kanazawa, T. Ohkubo, K. Sugawara The effect of grapefruit juice on the pharmacokinetics of erythromycin Eur J Clin Pharmacol 56 2001 799 803
42. D.R. Abernethy, D.L. Wesche, J.T. Barbey, C. Ohrt, S. Mohanty, J.C. Pezzullo Stereoselective halofantrine disposition and effect concentration-related QTc prolongation Br J Clin Pharmacol 51 2001 231 237
43. J.P. Saul, B. Ross, M.S. Schaffer, L. Beemann, A.P. Melikian, J. Shi Pediatric Sotalol Investigators. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia Clin Pharmacol Ther 69 2001 145 157
44. B. Evelyn, T. Toigo, D. Blanks, D. Pohl, K. Gray, B. Robins US Food and Drug Administration. Center for Drug Evaluation and Research Women's participation in clinical trials and gender-related labeling a review of new molecular entities approved 1995-1999 2001 Aug 24, Available from: URL: www.fda.gov/cder/reports/womens_health/women_clin_trials.htm. Accessed Oct 11, 2005
45. J.R. Swann, P.F. Reinstein Annual adverse drug experience report FDA report 1992 Food and Drug Administration Rockville (MD)
46. R.M. Martin, P.N. Biswas, S.N. Freemantle, G.L. Pearce, R.D. Mann Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England analysis of 48 cohort studies Br J Clin Pharmacol 46 1998 505 511
47. M.M. Van Riemsdijk, J.M. Ditters, M.C.J.M. Sturkenboom, J.H.M. Tulen, R.J. Ligthelm, D. Overbosch Neuropsychiatric events during prophylactic use of mefloquine before travelling Eur J Clin Pharmacol 58 2002 441 445
48. J.A. Sloan, R.M. Goldberg, D.J. Sargent, D. Vargas-Chanes, S. Nair, S.S. Cha Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer J Clin Oncol 20 2002 1491 1498
49. M.D. Drici, N. Clement Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome Drug Saf 24 2001 575 585
50. M.-L. Chen, S.-C. Lee, M.-J. Ng, D.J. Schuirmann, L.J. Lesko, R.L. Williams Pharmacokinetic analysis of bioequivalence trials implications for sex-related issues in clinical pharmacology and biopharmaceutics Clin Pharmacol Ther 68 2000 510 521
51. A. Heiat, C.P. Gross, H.M. Krumholz Representation of the elderly, women, and minorities in heart failure clinical trials Arch Intern Med 162 2002 1682 1688
52. S. Bandyopadhyay, A.J. Bayer, M.S. O'Mahony Age and gender bias in statin trials QJM 94 2000 127 132
53. P.Y. Lee, K.P. Alexander, B.G. Hammill, S.K. Pasquali, E.D. Peterson Representation of elderly persons and women in published randomized trials of acute coronary syndromes JAMA 286 2001 708 713
54. T. Trenque, N. Simon, I. Villena, C. Chemla, C. Quereux, B. Leroux Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis Br J Clin Pharmacol 57 2004 735 741
55. I. Mahmood, V. Tammara A comparison of two sparse sampling population pharmacokinetic approaches for the estimation of pharmacokinetic parameters in children Int J Clin Pharmacol Ther 42 2004 240 245
56. K.N. Atuah, D. Hughes, M. Pirmohamed Clinical pharmacology special safety considerations in drug development and pharmacovigilance Drug Saf 27 2004 535 554
57. The University of Arizona Center for Education and Research on Therapeutics © 2002 Arizona CERT 2005 Updated July 26, Availabe from URL: www.torsades.org. Accessed Oct 11, 2005